Terminal complement complex C5b-9 and C5b assay in sera of COVID-19 patients with different disease severities
Objective: The aim of this study is to find out the link between the involvement of complement activation in the inflammatory reactions in COVID-19 patients, the deterioration of the clinical status and development of sever COVID-19 in those patients. Methodology: The study included 274 COVID-19 pat...
Autors principals: | Asmaa Nasr El-Din, Kamal Ata |
---|---|
Format: | Article |
Idioma: | English |
Publicat: |
Zagazig University, Faculty of Medicine
2022-10-01
|
Col·lecció: | Microbes and Infectious Diseases |
Matèries: | |
Accés en línia: | https://mid.journals.ekb.eg/article_261883_a3edd5e4a63df2c2e4e6c70bfc4b4951.pdf |
Ítems similars
-
Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention
per: Zvi Fishelson, et al.
Publicat: (2019-04-01) -
Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species
per: Wioleta M. Zelek, et al.
Publicat: (2020-12-01) -
Biomarkers of the Complement System Activation (C3a, C5a, sC5b-9) in Serum of Patients before and after Liver Transplantation
per: Marta Budkowska, et al.
Publicat: (2023-07-01) -
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
per: Guo-Qing Tang, et al.
Publicat: (2023-08-01) -
Complement inhibition by anti-C5 antibodies - from bench to bedside and back again
per: Swiss Medical Weekly
Publicat: (2007-07-01)